Martine Rothblatt, Chairperson & Chief Executive Officer of United Therapeutics Corp (UTHR, Financial), executed a sale of 30,000 shares in the company on March 18, 2024, according to a recent SEC Filing. United Therapeutics Corp is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Over the past year, the insider has sold a total of 389,300 shares and has not made any purchases of the company's stock. The recent transaction further adds to the insider's sell trend over the past year, which includes 52 insider sells and no insider buys.
On the date of the insider's latest transaction, shares of United Therapeutics Corp were trading at $235.54, giving the company a market capitalization of $11.27 billion. The stock's price-earnings ratio stands at 12.07, which is lower than the industry median of 29.51 and also below the company's historical median price-earnings ratio.
According to the GuruFocus Value indicator, with a share price of $235.54 and a GF Value of $270.42, United Therapeutics Corp has a price-to-GF-Value ratio of 0.87, suggesting that the stock is modestly undervalued. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
The insider's recent sale could be interpreted in various ways by investors. While it may raise questions about the insider's confidence in the company's future prospects, it is also important to consider the overall insider transaction history and the company's current valuation metrics.
Investors and analysts often monitor insider transactions as they can provide insights into a company's internal perspective. However, it is crucial to look at a broader set of data and not make investment decisions based solely on insider activity.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
